



RDT[™]
RAPID DOSE THERAPEUTICS

COMPANY PRESENTATION MARCH 2020

CSE DOSE

FORWARD LOOKING STATEMENTS

This document is a presentation (the “Corporate Presentation”) of general background information about the current activities of Rapid Dose Therapeutics (RDT) Canada Inc. (“RDT”) as of the date here-of. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. This Corporate Presentation should be considered, with or without professional advice, when considering the business and prospects of RDT. This Corporate Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for securities nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. Recipients of this Corporate Presentation who are considering acquiring securities and assessing the business of RDT are reminded that any such assessment must not be made on the basis of the information contained in this Corporate Presentation but are referred to the entire body of publicly disclosed information regarding RDT.

Cautionary Note Regarding Forward-Looking Statements: Certain statements in this Corporate Presentation contain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Any statements that are contained in this Corporate Presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often, although not always, identified by terms such as “planned”, “enabled”, “opportunity”, “may”, “should”, “would”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this Corporate Presentation include, but are not limited to statements with respect to growth of the QuickStrip™ brand, consumer adoption rates, distribution plans of RDT’s customers, future market growth rates, geographic expansion plans and financial projections. The financial projections in this Corporate Presentation are provided for the purpose of assisting readers to evaluate RDT’s potential financial prospects under various revenue scenarios and such financial projections may not be appropriate for any other purpose. Such forward-looking statements, including, without limitation, in respect of the delivery of products using the QuickStrip™ product delivery method, express, as at the date of this Corporate Presentation, the plans, estimates, forecasts, projections, expectations or beliefs of RDT as to future events or results and are believed to be reasonable based on information currently available to RDT management. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this Corporate Presentation, including assumptions regarding expected growth, results of operations, performance, industry trends and growth opportunities for RDT and the markets in does business in. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical and recreational marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada and the U.S. generally; income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that the forward-looking statements contained herein, although considered reasonable by management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this Corporate Presentation are expressly qualified by this cautionary note. These forward-looking statements are made as of the date of this Corporate Presentation and RDT assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as expressly required by applicable law.

RAPID DOSE THERAPEUTICS

We are a Canadian life sciences company providing innovative, proprietary drug delivery technologies-designed to enhance therapeutic outcomes and quality of life for patients and consumers.

RDT's business verticals include **cannabis, nutraceutical and pharmaceutical** markets.



QuickStrip™

RDT's flagship product 'QuickStrip™' is a **thin, oral, dissolvable film**, which can quickly deliver active ingredients into the bloodstream, bypassing digestion / first-pass metabolism resulting in enhanced bio-availability and rapid onset of the active ingredient.

AT A GLANCE

Founded: May 3, 2017

Number of employees: 17

Publicly Traded: as of December 17, 2018

Ticker symbol: CSE:DOSE

Shares Issued & Outstanding: 77,067,435

Options outstanding:
3,986,000 @ \$0.82 expiring March 11, 2024
250,000 @ \$0.82 expiring July 29, 2024

Share Fully Diluted: 81,303,435

Insider Ownership: 37%

WHY INVEST

- **Licensed LP with attractive revenue growth potential**
Clear strategic vision and path to profitability driven by innovative products, expanding global distribution channels and white label manufacturing.
- **Products**
Premium portfolio of high-quality unique health & wellness precisely dosed oral dissolvable film products that include both nutraceutical, cannabis and pharmaceutical pipeline – application of technology is virtually **unlimited**.
- **Distribution**
Canadian brand partnerships to produce and distribute cannabis QuickStrip™ products. Nutraceutical distribution with Perennial Brands throughout Canada, US and India.
- **Global customers**
Quality cannabis companies: Aphria, Thrive, Flower One, Chemosis (California, Puerto Rico, Michigan)
Nutraceutical: Retailers and e-commerce across Canada.
- **Experienced management team**
Leadership team with decades of experience in operations, finance, business development, communications, marketing, and distribution.

ROADMAP FOR GROWTH

2018



Definitive contract signed with Chemesis for the state of California



Researching polymer thin film technology for oil-based therapeutics delivery



Top Ten New Product awarded by Grocery Innovation Canada (GIC) for non-food category

CSE:DOSE



UNLV and RDT conduct novel research to evaluate innovative Quickstrip™ Delivery



Definitive contract signed with agreement with Aphria Canada



Definitive contract signed with Chemesis for the Puerto Rico



Rapid Dose Therapeutics Begins Trading on the CSE Under the Ticker "DOSE"

2019



Definitive Agreement signed for innovative Quickstrip™ product to the Nevada cannabis market with brand relationship with Flower One



Research & Development methods for total synthesis of high purity cannabinoids and derivatives (underway)



Definitive contract signed with Chemesis for the state of Michigan

TRADEMARKS

19 trademarks filed in the US, Canada, and EU

PATENTS

1 non-provisional PCT patent application filed

4 provisional U.S. patent applications filed

EXPANSION OF OPERATIONS

for additional 50,000 sq ft. production for QuickStrip™ technology and pipeline products



RDT & Thrive Cannabis sign Manufacturing Agreement for Quickstrip™ cannabis products



Commences Clinical Research Trial with GI Research Institute and University of British Columbia



RDT and UNLV Research results published in Frontiers in Pharmacology Journal



Health Canada grants Micro-Processing licence to RDT

2020



RDT and McMaster University Awarded NSERC Research & Development grant to develop oral dissolvable film for enhanced drug delivery



RDT receives funding for scale-up manufacturing and commercialization of Quickstrip™ Product



RDT receives CRA Cannabis license enabling cannabis processing and packaging for Canada



RDT announces Nutraceutical Reseller Agreement for Canada, United States and India



Planned QuickStrip™ commercial cannabis launch across Canada

VERTICALS

RDT's business verticals — delivering health and therapeutic applications.



Nutraceuticals

OTC product portfolio (NPN, Health Canada approved)

- QuickStrip™ Energy (Caffeine)
- QuickStrip™ B12
- QuickStrip™ Sleep (Melatonin)
- Other QuickStrip™ OTC products in the pipeline
- Primary OTC targets for RDT are the large CDN US retail chains selling high volume consumer oriented products



Cannabis

- QuickStrip™ medical and recreational markets
- RDT licenses proprietary QuickStrip™ technology under a Managed Strip Services Contract (MSS) – this enables a recurring revenue model
- QuickStrip™ — The Quick, Convenient, Precise and Discreet™ Smoke Free Choice™ for consumers



Pharmaceutical

- Branded drug manufacturers seeking alternative delivery to expand or enhance products where rapid dosage or simplified delivery are important factors.
- Opportunity for branded products in mid-cycle, near patent expiry, or line extension.



Research Services

- Research and development services to outside companies requiring custom formulations for delivery applications
- Experienced in-house formulation scientists and analysis expertise to support unique and proprietary product development

CONSUMER PROBLEMS

- **Over 40% of population have difficulty swallowing pills^{1,2}**, from medical condition dysphagia to pill fatigue
- Medical conditions that affect the absorption of nutrients through the GI such as IBD, IBS, among others
- Chronic pain patients **desire a fast, effective and easy way to take therapeutics that delivers rapid relief** and does not affect the liver
- Cannabis and nicotine consumers desire alternative delivery method to avoid smoking or vaping for health reasons and for geo-location reasons (such as public spaces, work environment, hospitals)

RDT'S SOLUTION


- Delivers the **active ingredient quickly into the bloodstream** through the oral mucosa, **bypassing first pass metabolism** (liver and GI tract)
- Enabling **rapid absorption, rapid onset** and **increased bioavailability**
- Provides **precise dosing**
- Provides a **convenient, and discreet non-inhalation**, delivery for both cannabis and nicotine consumers



[1] Harris Interactive Report [2] [Pill Swallowing by Adults With Dysphagia](#)

QUICKSTRIP™ ENHANCED DELIVERY

- QuickStrip™ delivers a **precise dose* quickly into the bloodstream** via sublingual (under the tongue) or buccal (inside the cheek)
- QuickStrip™ **bypasses digestion in stomach.*** (first-pass metabolism)
- QuickStrip™ delivers **more* of the active ingredient per dose into your system** compared to direct to stomach — where it is degraded by digestion
- QuickStrip™ delivery ensures the **rapid onset of effect.***



*Hines, et al. *Frontiers in Pharmacology*, 10 September 2019; “Administration of Micronized Caffeine Using a Novel Oral Delivery Film Results in Rapid Absorption and Electroencephalogram Suppression”.

QUICKSTRIP™ CANNABIS DELIVERY BENEFITS



QuickStrip™ vs smoke and vape

- QuickStrip™ is completely a non-inhalation delivery system
- Inhalable products can cause odour and are not location-friendly being banned in public locations, workplaces, condos and hospitals
- Inhalation delivery dosing can be variable dependant on each user
- Reduces health risk from smoking or vaping and consume cannabis
- QuickStrip™ never enters your lungs and completely avoids inhalation of harmful additives.



QuickStrip™ vs pills, drinks and gummies

- Pills, drinks and gummies enter the digestive system where the actives are broken down resulting in **LESS BIOAVAILABILITY** of the active ingredient being delivered to the body
- Any active ingredient of a product being digested through the stomach takes **LONGER** to take effect
- In contrast **SUBLINGUAL DELIVERY** works well by avoiding the gastrointestinal system, and delivering **MORE** of the active ingredient into the body **RAPIDLY**




QuickStrip™ vs transdermal patches

- Transdermal patches must pass through the many layers of the skin to deliver the active ingredient, resulting in again **LESS BIOAVAILABILITY** of the active ingredient being delivered to the body.
- Transdermal delivery is generally designed to be **SLOW RELEASE** vs a quick release of active ingredients through sublingual delivery.
- Patches adhere to the skin and can cause skin irritation or allergic reaction due to the adhesives and latex used.



Cannabis sublingual delivery **AVOIDS** the gastrointestinal system, where ingestion may convert Delta 9 –THC into the more potent, compound — **11-hydroxy (11-OH THC)¹**, and may produce an undesirable intense, and long lasting psychoactive high. ^{2, 3, 4}



REFERENCES [1] Wikipedia [2] Grotenhermen F, et al, Pharmacokinetics and pharmacodynamics of cannabinoids. PubMed PMID: 1264802. [3] Heustis MA, et al. Blood Cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. PubMed. PMID: 1338215 [4] Wall ME, et al. The Metabolism of Delta-9-Tetrahydrocannabinol and Related Cannabinoids in Man. PubMed PMID: 6271823.

REVOLUTIONIZING CANNABIS DELIVERY

QuickStrip™

Quick,
Convenient,
Precise,
Discreet™

The
Smoke-Free
Choice™
for cannabis
consumers

THC Formulations

Micro-dosing: 2.5mg, 5mg
and 10mg

CBD Formulations

Micro-dosing: 2.5mg, 5mg, 10mg
and larger dose of 20mg

Available in various flavours



RDT provides the proprietary QuickStrip™ technology under a Managed Strip Services Contract (MSS) – this enables a recurring revenue model

QUICKSTRIP™ BASED ON SCIENCE

- QuickStrip™ is produced with a proprietary technology that **micronizes the active ingredient and evenly disperses** throughout the strip.
- The **small particle size** of the active ingredient **enhances the sublingual delivery in the mouth, then into the bloodstream.**

-
- **A bioanalytical study** was conducted in collaboration with researchers from University of Nevada, Las Vegas (UNLV) **to evaluate the QuickStrip™ oral thin film delivery system**, in mice, of caffeine (QuickStrip™ Energy) for onset time, bioavailability, and effects on the central nervous system **compared to direct administration into the stomach** via the gavage method.
 - The results demonstrated that the caffeine **QuickStrip™ technology, gave an overall 30% more bioavailability than direct to stomach, with rapid effect to the central nervous system.**



[Read the full article](#)

 **frontiers**
in Pharmacology

UNLV

 **RDT**
RAPID DOSE THERAPEUTICS

QUICKSTRIP™ NUTRACEUTICAL PRODUCTS

(NPN, Health Canada approved)

Nutraceutical line enables education and awareness of the QuickStrip™ brand and delivery benefits brand

Retail distribution and e-commerce



CANNABIS BRANDS POWERED BY QUICKSTRIP™



Being is a holistic, purposeful and active approach to improving lives through cannabis-based wellness therapies.



VEGAS STRIP offering consumers a lifestyle, social brand offered to the Nevada market delivering THC products



CANADIAN RETAIL LOCATIONS



Drug Independents (Ontario)

Pharmasave	(National – 37 locations)
Astra Pharmacy	Brampton
Remedy's Rx	Burlington
East Waterdown Pharmacy	Hamilton
Millcroft Pharmacy	Burlington
Medexpress Pharmacy	Burlington
Campbellville Pharmacy	Campbellville
LSV Pharmacy	Burlington
Carlisle Pharmacy	Carlisle
Glenashton Pharmacy	Oakville
River Oaks Pharmacy	Oakville
IDA	Hamilton
IDA	Toronto

Grocery

Foodland	Thorold
Foodland	Smithville
Summerhill Market	Toronto

Convenience/C-Store

INS Market	(National)
International News	(National)
Big Bee Convenience	(Hamilton)
KC's Variety	(Burlington)



RDT'S PROPRIETARY TECHNOLOGY AND MANUFACTURING SOLUTION

Film casting, slitting and packaging equipment are custom-designed for high-throughput production of QuickStrip™ oral dissolvable film strips

- Remote production at our licensed global customer sites, through a Managed Strip Service Agreement (MSSA).
- White-label manufacturing (WLM) at RDT headquarter site (Burlington, Ontario)




RECURRING BUSINESS MODEL

RDT'S MANAGED STRIP SERVICE AGREEMENT (MSSA)



RDT charges a recurring service fee to licensed cannabis producers and growers globally, for production of RDT's proprietary QuickStrip™ technology under a Managed Strip Service Agreement (MSSA)

MSSA service-fee
paid to RDT for each QuickStrip™
produced by customers
(production to be monitored via IOT)



The image features a vibrant yellow background with a gradient. Scattered across the scene are several golden, glowing molecular models. Each model consists of a central, larger sphere connected to three smaller spheres by thin, metallic-looking rods. The spheres have a textured, crystalline appearance with small dark spots and bright highlights, giving them a three-dimensional, shimmering effect. The lighting is soft and diffused, creating a warm, ethereal atmosphere. The word "APPENDIX" is centered in the middle of the image in a bold, blue, sans-serif font.

APPENDIX

QUICK. CONVENIENT. PRECISE. DISCREET.™

QUICK

No swallowing required!

Dissolves in your mouth, or under your tongue, in seconds.

Delivers more cannabis product directly to the body while providing fast results.



CONVENIENT

Melts in your mouth!

Easy to take, no swallowing, no water required.

Individually packaged, single dosed in a child-resistant, sealed pouch.



PRECISE

Takes the guesswork out of dosing!

Unlike oils, sprays and edibles, QuickStrip™ prevents active ingredient degradation in the stomach from first pass metabolism.

Precisely dosed strips are easy to take.



DISCREET

No Smoke. No Smell. No Stigma.™


QuickStrip™ can be enjoyed and consumed responsibly in a discreet way.

Anytime, Anywhere



FOR EVERY PART OF YOUR DAY or NIGHT

ALTERNATIVE FORMAT OPPORTUNITY TINCTURE & SUBLINGUAL




- Global issues surrounding smoking & vaping
- Deloitte projects more than half of the estimated \$2.7-billion Canadian market will be spent on alternative cannabis products.
- Deloitte also estimates the legal medical cannabis Canadian market to be worth C\$0.77 billion to C\$1.79 billion

Source: [Nurturing New Growth: Canada gets ready for Cannabis 2.0](#),
[Deloitte](#)

Deloitte states in their 2019 Cannabis report:

“Introducing alternative cannabis products will enable Canadian companies to realize even more of that potential market in the months and years to come.”

QUICKSTRIP™ NUTRACEUTICAL VIDEO



COPYRIGHT OF RAPID DOSE THERAPEUTICS CORP.

CORPORATE VIDEO



COPYRIGHT OF RAPID DOSE THERAPEUTICS CORP.



INVESTOR RELATONS CONTACT INFORMATION

Rapid Dose Therapeutics Corp.

1121 Walkers Line, Unit 3A

Burlington ON L7N 2G4

Rapid-Dose.com

QuickStrip.life

For inquiries:

Mark Upsdell, CEO

mupsdell@rapid-dose.com

CSE: DOSE